Healthcare -
Biotechnology - NASDAQ - US
$ 1.125
-1.82 %
$ 3.31 M
Market Cap
None
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
CNS Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 14.9 M |
| Operating Income | -14.9 M |
| Other Expenses | -44.1 K |
| Net Income | -14.9 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||||||
| Cost Of Revenue | 0 | 4.13 K | 11.8 K | 13.1 K | 11.1 K | 1.96 K | 0 | 0 |
| Gross Profit | 0 | 4.13 K | 11.8 K | 13.1 K | 11.1 K | 1.96 K | 0 | 0 |
| OPERATING INCOME | ||||||||
| Operating Expenses | 14.9 | 18.9 | 15.3 | 14.0 | 9.5 | 3.8 | 0.9 | 0.2 |
| Selling, General and Administrative Expenses | 5.6 | 4.8 | 6.0 | 4.7 | 4.4 | 2.0 | 0.9 | 0.2 |
| Research and Development Expenses | 9.3 | 14.1 | 9.3 | 9.3 | 5.1 | 1.9 | 21.3 K | 32.6 K |
| Operating Income | (14.9) | (18.9) | (15.3) | (14.0) | (9.5) | (3.8) | (0.9) | (0.2) |
| PRE-TAX INCOME | ||||||||
| Interest Income Expense | 16.1 K | 0 | 7.03 K | 9.28 K | 3.26 K | 44.2 K | 46.7 K | 0 |
| Total Other Income | 44.1 K | 13.9 K | 7.03 K | 9.28 K | 3.26 K | 44.2 K | (6.5) | 4.26 K |
| Pre-Tax Income | (14.9) | (18.9) | (15.3) | (14.0) | (9.5) | (3.9) | (7.4) | (0.2) |
| NET INCOME | ||||||||
| Tax Provision | 0 | 0 | 7.03 K | 9.28 K | 3.26 K | 42.3 K | 46.7 K | (0.5) |
| Net Income | (14.9) | (18.9) | (15.3) | (14.5) | (9.5) | (3.9) | (7.4) | (0.5) |
| EPS | 38.9 | 251 | 561 | 853 | 860 | 354 | 674 | 48 |